These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

592 related items for PubMed ID: 25511804

  • 1. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
    Castro-Hernández J, Afonso-Oramas D, Cruz-Muros I, Salas-Hernández J, Barroso-Chinea P, Moratalla R, Millan MJ, González-Hernández T.
    Neurobiol Dis; 2015 Feb; 74():325-35. PubMed ID: 25511804
    [Abstract] [Full Text] [Related]

  • 2. Prolonged dopamine D3 receptor stimulation promotes dopamine transporter ubiquitination and degradation through a PKC-dependent mechanism.
    Luis-Ravelo D, Fumagallo-Reading F, Castro-Hernandez J, Barroso-Chinea P, Afonso-Oramas D, Febles-Casquero A, Cruz-Muros I, Salas-Hernandez J, Mesa-Infante V, Rodriguez-Nuñez J, Gonzalez-Hernandez T.
    Pharmacol Res; 2021 Mar; 165():105434. PubMed ID: 33484816
    [Abstract] [Full Text] [Related]

  • 3. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN, Woolsey C, Ryoo H, Borwege S, Hagner D.
    BMC Biol; 2004 Oct 11; 2():22. PubMed ID: 15473914
    [Abstract] [Full Text] [Related]

  • 4. Dopamine transporter is downregulated and its association with chaperone protein Hsc70 is enhanced by activation of dopamine D3 receptor.
    Chang PK, Chien KY, Chen JC.
    Brain Res Bull; 2020 Dec 11; 165():263-271. PubMed ID: 33049353
    [Abstract] [Full Text] [Related]

  • 5. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M, Kitamura Y, Tamaki A, Yanagida T, Shibaike T, Yamamoto A, Takata K, Yasui H, Taira T, Ariga H, Taniguchi T.
    Neurochem Int; 2009 Dec 11; 55(8):760-7. PubMed ID: 19647776
    [Abstract] [Full Text] [Related]

  • 6. Transient and rapid activation of Akt/GSK-3β and mTORC1 signaling by D3 dopamine receptor stimulation in dorsal striatum and nucleus accumbens.
    Salles MJ, Hervé D, Rivet JM, Longueville S, Millan MJ, Girault JA, Mannoury la Cour C.
    J Neurochem; 2013 May 11; 125(4):532-44. PubMed ID: 23410496
    [Abstract] [Full Text] [Related]

  • 7. Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice.
    Le Foll B, Diaz J, Sokoloff P.
    Life Sci; 2005 Jan 28; 76(11):1281-96. PubMed ID: 15642598
    [Abstract] [Full Text] [Related]

  • 8. Long-term controlled GDNF over-expression reduces dopamine transporter activity without affecting tyrosine hydroxylase expression in the rat mesostriatal system.
    Barroso-Chinea P, Cruz-Muros I, Afonso-Oramas D, Castro-Hernández J, Salas-Hernández J, Chtarto A, Luis-Ravelo D, Humbert-Claude M, Tenenbaum L, González-Hernández T.
    Neurobiol Dis; 2016 Apr 28; 88():44-54. PubMed ID: 26777664
    [Abstract] [Full Text] [Related]

  • 9. Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons.
    Bono F, Savoia P, Guglielmi A, Gennarelli M, Piovani G, Sigala S, Leo D, Espinoza S, Gainetdinov RR, Devoto P, Spano P, Missale C, Fiorentini C.
    Mol Neurobiol; 2018 Feb 28; 55(2):1054-1067. PubMed ID: 28092083
    [Abstract] [Full Text] [Related]

  • 10. Dopamine D3 autoreceptor inhibition enhances cocaine potency at the dopamine transporter.
    McGinnis MM, Siciliano CA, Jones SR.
    J Neurochem; 2016 Sep 28; 138(6):821-9. PubMed ID: 27393374
    [Abstract] [Full Text] [Related]

  • 11. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
    Aloisi G, Silvano E, Rossi M, Millan MJ, Maggio R.
    Neuropharmacology; 2011 Sep 28; 60(2-3):439-45. PubMed ID: 21035472
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
    Matsukawa N, Maki M, Yasuhara T, Hara K, Yu G, Xu L, Kim KM, Morgan JC, Sethi KD, Borlongan CV.
    Brain Res; 2007 Jul 30; 1160():113-23. PubMed ID: 17573046
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
    González H, Contreras F, Prado C, Elgueta D, Franz D, Bernales S, Pacheco R.
    J Immunol; 2013 May 15; 190(10):5048-56. PubMed ID: 23589621
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.